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Summary
Objectives: The aim of this study was to evaluate the safety and immunogenicity of DTPa—HBV
and Hib vaccines given mixed or separately to 360 healthy infants at 2, 4, and 6 months of age.
Methods: Immune memory was assessed in lower responders (post-primary anti-PRP <0.545 mg/
ml), through administration of plain polyribosylribitol phosphate (PRP) at 12—15 months. All
subjects received a DTPa—HBV/Hib booster at 18—19 months.
Results: One month after primary vaccination, 98% had seroprotective antibody levels against
HBV and 94—97% against Hib (anti-PRP  0.15 mg/ml). A statistically significant difference
between groups was observed in the proportion of subjects who achieved anti-PRP antibodies
1.0 mg/ml post-primary vaccination; 68.1% for DTPa—HBV/Hib and 84.5% for DTPa—HBV and
Hib. PRP administered to lower responders produced a 7-fold increase in anti-PRP antibodies,
indicative of immunological memory. After DTPa—HBV/Hib booster vaccination, 96—100% of
subjects had seroprotective antibody concentrations against Hib, hepatitis B, tetanus, and
diphtheria and high vaccine response rates against pertussis toxoid, filamentous hemagglutinin,
and pertactin.
* Corresponding author. Tel.: +61 8 8161 8115; fax: +61 8 8161 7031.
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Conclusion: A robust and protective Hib response was demonstrated following plain PRP and/or a
booster conjugate Hib vaccine in both lower and higher Hib responders.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The National Immunisation Program in Australia currently
recommends primary vaccination with diphtheria, tetanus
and acellular pertussis (DTPa), inactivated polio vaccine
(IPV), hepatitis B virus (HBV), Haemophilus influenzae type
b (Hib), rotavirus and 7-valent pneumococcal conjugate
vaccines for infants.1 A booster dose of Hib is provided at
12 months of age in addition to meningococcal C vaccine and
measles, mumps and rubella vaccine. The combination DTPa
vaccine was introduced as the standard recommendation in
Australia in 1997—1999.2 A national program for Hib vaccina-
tion was begun in 1993, and has resulted in substantial
reductions in invasive Hib disease.3
The increasing number of vaccines available for immuni-
zation against numerous childhood diseases has the effect of
making vaccination schedules progressively more complex,
which may be a significant barrier to the success of immu-
nization programs.4 The large number of injections required
if each vaccine is administered separately can also be a
source of distress to parents and children.5 The use of
combination vaccines can reduce the number of injections,
simplify immunization schedules, reduce the risk of delayed
doses, improve patient convenience by requiring fewer clinic
visits, reduce the perceived pain and distress for the child,
and reduce costs associated with vaccine administration.6 A
study of infant immunization in Sydney found that adminis-
tration of DTP, Hib and HBV vaccines was often fragmented
across separate visits, with a risk of missed or delayed doses,
and concluded that there was a need for a combination
DTPa—HBV—Hib vaccine.7
Earlier studies have established the effectiveness of a
quadrivalent DTPa—HBV vaccine8 and the feasibility of com-
bining DTPa—HBV and Hib vaccines in a single injection for
primary vaccination in healthy infants.9—12
Although the purpose of combination vaccines is to reduce
the number of needles administered to children, it is essen-
tial that vaccine efficacy is not compromised. It has pre-
viously been documented that combining Hib tetanus
conjugated vaccines with DTPa vaccines can result in a lower
level of circulating antibodies to the capsular polysaccharide
polyribosylribitol phosphate (PRP) compared to separate
administration of the vaccines. The reasons for the decrease
in antibody response in some DTP/Hib combination vaccine
studies remain unclear, but the variation in results observed
suggests these differences are vaccine-specific.13 Possible
reasons for decreased immunogenicity of Hib in DTPa com-
bination vaccines include direct interference between dif-
ferent antigens when mixed, epitope-specific suppression,
and/or variation in adjuvants in vaccines studied.13 However
the variability in response is unlikely to be of any clinical
significance as the protective efficacy of DTPa—Hib combina-
tion vaccines with lower antibody concentrations has been
established.14,15 In addition, immunological memory has
been demonstrated in studies where contact with unconju-gated (plain) PRP antigen following priming with a combina-
tion Hib vaccine has resulted in induced functional Hib
antibody.16 Plain PRP used in this study and in others as an
immunological challenge, is used to mimic exposure to wild-
type Hib infection as a method of assessing immunological
memory.17,18
Data have also shown that when corrected for total anti-
body level, anti-PRP antibody avidity does not differ with
different methods of administration including administration
of Hib separately or in combination.14
The aim of this study was to investigate the immunogeni-
city and reactogenicity of a candidate Hib vaccine and
quadrivalent DTPa—HBV vaccine given either as a single
mixed injection or administered simultaneously in opposite
limbs for primary vaccination to healthy infants at 2, 4, and 6
months of age. A follow-up booster study was conducted in
which the DTPa—HBV and Hib vaccines were administered as
a single injection to the same subjects during the second year
of life.
Materials and methods
Study design and subjects
The primary vaccination study (208140/039) was an open-
label, randomized, comparative trial conducted in two cen-
ters in Australia. Healthy infants of either sex, and aged
between 8 and 12 weeks at the time of first immunization,
were randomized to receive either a single vaccination with
combined DTPa—HBV/Hib or separate injections of DTPa—
HBV and Hib in opposite thighs, at 2, 4 and 6 months of age.
Subjects were excluded if they had obvious health problems
established by clinical examination and/or medical history,
or if they had a history of previous exposure to diphtheria,
tetanus, pertussis, hepatitis B, or Hib vaccination or disease.
Subjects completing the primary vaccination study were
eligible to enter an open-label booster study conducted at
the same centers (208108/043) and to receive a single
injection of DTPa—HBV/Hib vaccine at 18—19 months of
age. To assess immune memory in subjects potentially at
risk (i.e., low anti-PRP response after primary vaccination),
40 subjects with anti-PRP values below 0.545 mg/ml after
primary vaccination (lower responders) received a dose of
plain PRP at 12—15 months of age following the primary
vaccination. The cut-off (0.545 mg/ml) was based on the
anti-PRP antibody responses of the first 100 subjects eval-
uated in the primary vaccination study and was chosen so as
not to challenge subjects who had already shown a very high
response to primary vaccination.
Both study protocols were approved by the ethics com-
mittee at each trial center, and the studies were conducted
in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines. The parent or guardian of each
subject provided written informed consent before any study
procedure was performed.
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All vaccines were manufactured by GlaxoSmithKline (GSK)
Biologicals, Rixensart, Belgium. The DTPa—HBV licensed vac-
cine contained, per 0.5 ml dose, diphtheria toxoid 30 IU,
tetanus toxoid 40 IU, pertussis toxoid (PT) 25 mg, filamen-
tous hemagglutinin (FHA) 25 mg, pertactin (PRN) 8 mg, and
recombinant surface antigen of the hepatitis B virus (HBsAg)
10 mg. The candidate Hib conjugate vaccine contained, per
lyophilized dose, PRP 10 mg conjugated to tetanus toxoid 20—
40 mg adsorbed onto aluminum salts as adjuvant, and lactose
10 mg. In addition to the study vaccines all infants received
oral polio vaccine in accordance with the Australian Standard
Vaccination Schedule.
Immunogenicity assessment
Blood samples for immunogenicity assessment were taken
immediately before the first primary vaccine dose and one
month after the third dose. In the booster study, blood
samples were taken before and one month after the
DTPa—HBV/Hib booster vaccine dose. In the subset of sub-
jects receiving plain PRP (10 mg), blood samples were also
taken before and 7—10 days after the dose of PRP.
Total antibodies to Hib PRP were measured using a radi-
olabeled antigen binding assay with a cut-off of 0.15 mg/ml.
Antibodies against HBsAg (anti-HBs) were determined using
a commercially available radioimmunoassay (AUSAB1,
Abbott Laboratories, Abbott Park, IL, USA) with a cut-off
of 10 mIU/ml. Antibody concentrations 10 mIU/ml were
considered as protective. Antibodies against diphtheria and
tetanus toxoids were measured by ELISA techniques, with a
cut-off level of 0.1 IU/ml. Antibodies (IgG) against PT, FHA,
and PRN (pertussis antigens), weremeasured by ELISAwith a
cut-off of 5 ELISA units (EL.U)/ml. A vaccine response to PT,
PRN, and FHA after the booster dose was defined as appear-
ance of antibodies in initially seronegative subjects or a 2-
fold increase in antibody concentration in initially seropo-
sitive subjects.
Safety and reactogenicity assessment
Diary cards were distributed to the parents or guardians to
record solicited and unsolicited symptoms and adverse
events. Reactogenicity was assessed by measuring the
appearance of solicited local symptoms (pain, redness,
or swelling at the injection site) or general symptoms
(irritability/fussiness, fever, vomiting, diarrhea, restless-
ness, sleepiness, unusual crying, drowsiness, and loss of
appetite) during a 4-day follow-up period after each vac-
cination dose. Unsolicited adverse events (AEs) and serious
adverse events (SAEs) were recorded throughout the study
period. Intensity was assessed on a three-point scale where
grade 3 intensity for solicited symptoms included crying
when the limb was moved or a spontaneously painful limb,
crying that could not be comforted or that prevented
normal everyday activity, drowsiness that prevented nor-
mal everyday activity, loss of appetite such that the study
subject did not eat at all. Local redness and swelling were
assessed by measuring the largest diameter, where grade 3
was >20 mm.Statistical analyses
The study was exploratory. Antibody seroprotection/seropo-
sitivity and vaccine response rates against vaccine antigens
for the according-to-protocol (ATP) cohort were calculated
with exact 95% confidence intervals (CI). Geometric mean
antibody concentrations (GMC) with 95% CI were calculated
from the anti-log of the mean of log-transformed values.
Antibody concentrations below the lower limit of detection
of the assay were assigned an arbitrary value of half the cut-
off for the purpose of GMC calculation.
Reactogenicity was evaluated by calculating the percen-
tage (and 95% CI) of doses followed by a report of at least one
solicited or unsolicited local or general symptom during the
defined follow-up period after vaccination. For each group,
the incidence of each symptom overall and rated as grade 3
was recorded. Values were considered as significantly differ-
ent between groups if the 95% CI did not overlap.
Results
Demographics
The primary study was conducted between November 1996
and January 1998, and enrolled 360 infants. The booster
study took place between January 1998 and January 1999
and included 276 subjects. Figure 1 presents the disposition
of subjects in both studies. All but three infants completed
the primary vaccination course (all were lost to follow-up).
The ATP cohort for immunogenicity comprised 328 (91.1%)
infants. Thirty-two subjects were excluded from the ATP
analysis (randomization failure (1), initially seropositive or
entry status unknown (4), prohibited medication (1), non-
compliant with vaccination or blood sampling schedule (21),
and essential serological data missing (5)).
In the primary study, the mean age at first dose was 8.6
weeks and 168/328 (51.2%) were male. The mean age at the
time of PRP challenge was 13.4 months in the subgroup that
received plain PRP vaccination, and themean age at the time
of booster vaccination was 17.9 months and 18.0 months in
the subjects primed with DTPa—HBV + Hib and DTPa—HBV/
Hib, respectively.
Immunogenicity
Primary vaccination
Anti-PRP and anti-HBs antibody concentrations were evalu-
ated prior to and after the primary vaccination course.
Seroprotection rates and GMCs one month after the third
dose of primary vaccination are presented in Table 1.
A total of 94.4% (95% CI 89.6—97.4%) of subjects in the
combined DTPa—HBV/Hib group had seroprotective antibody
concentrations against Hib (anti-PRP 0.15 mg/ml) com-
pared with 97.6% (95% CI 94.0—99.3%) in the group receiving
separate injections. A higher proportion of subjects in the
group that received separate injections reached an antibody
level against PRP of 1.0 mg/ml (84.5%, 95% CI 78.2—89.6%)
compared with the group that received the combined injec-
tion (68.1%, 95% CI 60.3—75.3%). The GMC for anti-PRP
antibodies was also higher in the group that received sepa-
rate injections (4.553 mg/ml (95% CI 3.647—5.685 mg/ml))
Figure 1 Disposition of subjects included in the primary and booster vaccination trials.
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(2.034 mg/ml (95% CI 1.574—2.628 mg/ml)).
Anti-HBs antibody levels of 10 mIU/ml one month after
the third dose were high in both groups, occurring in 98.8% of
subjects receiving a single injection and 98.2% of subjects
receiving separate injections.
Plain PRP challenge: assessment of immune memory
Infants younger than 18—24 months of age cannot mount a
seroprotective response to plain polysaccharides such as PRPunless immune memory has been previously primed. The
presence of immune memory was assessed in the subset of
40 subjects that were lower responders, by measuring the
increase in anti-PRP antibody concentrations 7 days after the
administration of plain PRP at 12—15 months of age. Twenty-
five lower responders had received priming with combined
DTPa—HBV/Hib vaccine and 15 had received DTPa—HBV + Hib
vaccines. The results show that after a PRP challenge, the
anti-PRP antibody GMC rapidly increased, indicating that
anti-PRP immune memory had been induced regardless of
Table 1 Seroprotection/seropositivity rates and antibody geometric mean concentrations one month after the third dose of
DTPa—HBV and Hib vaccines (ATP cohort for immunogenicity)
DTPa—HBV/Hib (N = 160) DTPa—HBV + Hib (N = 168)
Antigen % 95% CI GMC 95% CI % 95% CI GMC 95% CI
Anti-PRP
0.15 mg/ml 94.4 89.6—97.4 2.034 1.574—2.628 97.6 94.0—99.3 4.553 3.647—5.685
1.0 mg/ml 68.1a 60.3—75.3 - - 84.5a 78.2—89.6 - -
Anti-HBs
10 mIU/ml 98.8 95.6—99.8 920.3 752.1—1126.1 98.2 94.9—99.6 783.6 629.7—975.0
DTPa—HBV, diphtheria, tetanus, acellular pertussis, hepatitis B vaccine; Hib, Haemophilus influenzae type b vaccine; ATP, according-to-
protocol; N, number of subjects with available results; 95% CI, 95% confidence interval; GMC, geometric mean concentration; anti-PRP,
antibodies to polyribosylribitol phosphate; anti-HBs, antibodies to the hepatitis B surface antigen.
a Statistically significant difference — 95% CI do not overlap.
Table 2 Anti-PRP seroprotection rates and antibody geometric mean concentrations after the plain PRP challenge in subjects
classified as lower responders (anti-PRP <0.545 mg/ml) one month after the primary vaccination course
Post-primary antibody concentration Anti-PRP 0.15 mg/ml GMC (mg/ml)
n % 95% CI GMC 95% CI
<0.15 mg/ml 7 85.7 42.1—99.6 0.372 0.155—0.893
0.15 to <0.545 mg/ml 32 96.9 83.8—99.9 1.296 0.729—2.305
Total 39 94.9 82.7—99.4 1.036 0.624—1.722
PRP, polyribosylribitol phosphate; GMC, geometric mean concentration; 95% CI, 95% confidence interval.
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DTPa—HBV + Hib (Table 2; Figure 2). Before the plain PRP
challenge, 50% (95% CI 33.4—66.6%) of the lower responders
had anti-PRP0.15 mg/ml, which rose to 94.9% (82.7—99.4%)
7 days post-PRP challenge (Table 2). Of low responders with
post-primary anti-PRP antibodies <0.15 mg/ml, 85.7%
achieved seroprotective concentrations after the challenge
dose. In low responders the anti-PRP antibody GMC increased
7-fold from 0.146 mg/ml (95% CI 0.113—0.187 mg/ml) pre-
vaccination to 1.036 mg/ml (95% CI 0.624—1.722 mg/ml)
post-vaccination.Figure 2 Individual responses to plain PRP challenge by vac-
cine used for primary vaccination. Post-dose 3 = one month after
primary vaccination; Pre-PRP and post-PRP = prior to and 7 days
after challenge with plain PRP at 12—15 months of age. Each line
represents results from an individual.Booster vaccination
Prior to booster dosing with DTPa—HBV/Hib, antibody per-
sistence was similar in both groups, irrespective of whether
the primary vaccination had been administered using sepa-
rate or single injections (Table 3). One month after booster
vaccination, substantial increases in all antibody concentra-
tions were observed. The percentage of subjects with anti-
PRP 1.0 mg/ml reached 98.2—100% after boosting. At least
99.1% of subjects had seroprotective antibody concentra-
tions against diphtheria, tetanus and hepatitis B after the
booster dose. Vaccine response rates as represented by anti-
PT, anti-FHA and anti-PRN antibody concentrations were also
high (over 96%). Overall, the immune response to the booster
dose was similar for the two comparative treatment groups.
Safety and reactogenicity
Primary vaccination
Primary vaccination was well tolerated in both groups
(Table 4). The incidence of grade 3 solicited symptoms was
low, and was similar in both groups (Table 4). There were no
statistically significant differences in reactogenicity between
the two groups.
The total number of unsolicited symptoms reported in the
30-day follow-up period after primary vaccination was 253 in
the group receiving the vaccines as a single injection and 228
in the group receiving separate injections.
A total of 27 SAEs were reported during the study. All
except one were considered unrelated to vaccination by the
investigator. One SAE was assessed as probably related, a
hypotonic hyporesponsive episode that occurred in the sepa-
rate vaccination group. The event lasted for 45 minutes,
Table 3 Seroprotection/seropositivity and antibody geometric mean concentrations before and one month after booster vaccination with DTPa—HBV/Hib vaccine in children aged
18—19 months (total cohort)
DTPa—HBV/Hib primed DTPa—HBV + Hib primed
Time point N % 95% CI GMC 95% CI N % 95% CI GMC 95% CI
Anti-PRP Pre-booster 103 81.6 72.7—88.5 0.464 0.365—0.591 113 86.7 79.1—92.4 0.481 0.383—0.604
0.15 mg/ml Post-booster 114 100.0 96.8—100.0 70.286 55.522—88.977 111 100.0 96.7—100.0 78.544 64.275—95.981
Anti-PRP Pre-booster 103 24.3 16.4—33.7 - - 113 23.0 15.6—31.9 - -
1.0 mg/ml Post-booster 114 98.2 93.8—99.8 - - 111 100.0 96.7—100.0 - -
Anti-T Pre-booster 105 74.3 64.8—82.3 0.158 0.134—0.187 112 88.4 81.0—93.7 0.235 0.201—0.274
0.1 IU/ml Post-booster 114 100.0 96.8—100 5.762 4.956—6.699 111 99.1 95.1—100 8.559 7.364—9.948
Anti-D Pre-booster 104 43.3 33.6—53.3 0.089 0.078—0.103 112 37.5 28.5—47.1 0.082 0.072—0.094
0.1 IU/ml Post-booster 114 100.0 96.8—100 4.369 3.712—5.143 111 100.0 96.7—100 3.422 2.912—4.022
Anti-HBs Pre-booster 105 85.7 77.5—91.8 76.7 55.4—106.2 113 88.5 81.1—93.7 70.8 53.8—93.4
10 mIU/ml Post-booster 114 100.0 96.8—100 2365.4 1696.7—3297.8 112 100.0 96.8—100 1568.4 1155.3—2129.3
Anti-PT Pre-booster 104 48.1 38.2—58.1 5.2 4.3—6.2 113 46.9 37.5—56.5 4.8 4.1—5.5
5 EL.U/ml Post-booster 114 100.0 96.8—100.0 70.3 60.6—81.6 111 99.1 95.1—100.0 61.9 53.0—72.3
VR Post-booster 104 96.2 90.4—98.9 - - 106 99.1 94.9—100.0 - -
Anti-FHA Pre-booster 101 99.0 94.6—100.0 40.2 33.5—48.1 108 100.0 96.6—100.0 41.1 35.3—47.8
5 EL.U/ml Post-booster 114 100.0 96.8—100.0 822.0 724.6—932.4 111 100.0 96.7—100.0 708.8 614.0—818.2
VR Post-booster 101 97.0 91.6—99.4 101 98.0 93.0—99.8
Anti-PRN Pre-booster 105 91.4 84.4—96.0 16.7 14.1—19.8 113 89.4 82.2—94.4 16.1 13.4—19.3
5 EL.U/ml Post-booster 114 100.0 96.8—100.0 776.4 659.6—913.8 111 100.0 96.7—100.0 632.7 530.3—754.8
VR Post- booster 105 99.0 94.8—100.0 - - 106 98.1 93.4—99.8 - -
DTPa—HBV, diphtheria, tetanus, acellular pertussis, hepatitis B vaccine; Hib, Haemophilus influenzae type b vaccine; N, number of subjects with available serology results at the specified time
point; %, percentage of subjects with specified antibody concentrations or vaccine response; 95% CI, 95% confidence interval; GMC, geometric mean concentration; anti-PRP, antibodies to
polyribosylribitol phosphate; anti-T, antibodies to tetanus toxoid; anti-D, antibodies to diphtheria toxoid; anti-HBs, antibodies to the hepatitis B surface antigen; anti-PT, antibodies to the
pertussis toxoid; anti-FHA, antibodies to filamentous hemagglutinin; anti-PRN, antibodies to pertactin; VR, vaccine response (appearance of antibodies in initially seronegative subjects or a 2-
fold increase in antibody concentration in initially seropositive subjects); EL.U, ELISA units; IU, international units.
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Table 4 Incidence of solicited local and general symptoms within the 4-day follow-up: primary vaccination (overall doses, ATP
reactogenicity cohort) and booster vaccination (total cohort)
Primary vaccination Booster vaccination with DTPa—HBV/Hib
DTPa—HBV/Hib
(N = 533)
DTPa—HBV + Hib (N = 538) DTPa—HBV/
Hib-primed (N = 116)
DTPa—HBV +
Hib-primed (N = 117)
DTPa—HBV Hib
Symptom % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Pain 19.5 16.2—23.1 16.5 13.5—20.9 12.6 10.0—15.7 50.0 40.6—59.4 53.8 44.4—63.1
Grade 3a 0.2 0.0—1.0 1.1 0.4—2.4 0.4 0.0—1.3 6.0 2.5—12.0 4.3 1.4—9.7
Redness 38.6 34.5—42.9 35.1 31.1—39.3 25.1 21.5—29.0 70.7 61.5—78.8 69.2 60.0—77.4
>20 mm 2.3 1.2—3.9 1.7 0.8—3.2 0.9 0.3—2.2 29.3 21.2—38.5 26.5 18.8—35.5
Swelling 25.3 21.7—29.2 23.4 19.9—27.2 11.0 8.5—13.9 54.3 44.8—63.6 56.4 46.9—65.6
>20 mm 4.5 2.9—6.6 3.7 2.3—5.7 0.4 0.0—1.3 25.9 18.2—34.8 25.6 18.0—34.5
Diarrhea 17.1 14.0—20.5 16.2 13.2—19.6 8.6 4.2—15.3 9.3 4.7—16.1
Grade 3b 0.4 0.0—1.3 0.4 0.0—1.3 0.0 0.0—3.1 0.0 0.0—3.1
Feverc
37.5 8C 14.4 11.6—17.7 11.2 8.6—14.1 18.1 11.6—26.3 16.9 10.7—25.0
>39.0 8C 0.4 0.0—1.3 0.7 0.2—1.9 0.9 0.0—4.7 2.5 0.5—7.3
Fussiness 52.0 47.6—56.3 54.6 50.3—58.9 51.7 42.3—61.1 44.1 34.9—53.5
Grade 3b 0.9 0.3—2.2 2.0 1.3—3.6 2.6 0.5—7.4 0.0 0.0—3.1
Loss of appetite 14.1 11.2—17.3 15.1 12.1—18.4 31.0 22.8—40.3 22.0 14.6—30.6
Grade 3b 0.4 0.0—1.3 0 0.0—0.7 1.7 0.2—6.1 1.7 0.2—6.0
Restlessness 31.5 27.6—35.7 31.8 27.9—35.9 26.7 18.9—35.7 31.4 23.1—40.5
Grade 3b 0.4 0.0—1.3 0 0.0—0.7 4.3 1.4—9.8 0.8 0.0—4.6
Sleeping more
than usual
28.1 24.4—32.2 28.3 24.5—32.3 19.8 13.0—28.3 16.1 10.0—24.0
Grade 3b 0.2 0.0—1.0 0.2 0.0—1.0 0.9 0.0—4.7 0.8 0.0—4.6
Unusual crying 37.0 32.9—41.2 40.7 36.5—45.0 10.3 5.5—17.4 7.6 3.5—14.0
Grade 3b 0.4 0.0—1.3 0.6 0.1—1.6 2.6 0.5—7.4 0.0 0.0—3.1
Vomiting 14.1 11.2—17.3 13.9 11.1—17.2 7.8 3.6—14.2 4.2 1.4—9.6
Grade 3b 0.4 0.0—1.3 0 0.0—0.7 0.9 0.0—4.7 0.0 0.0—3.1
ATP, according-to-protocol; DTPa—HBV, diphtheria, tetanus, acellular pertussis, hepatitis B vaccine; Hib, Haemophilus influenzae type b
vaccine; N = total number of diary cards returned following all doses (results presented from subjects who did not receive PRP challenge);
95% CI, 95% confidence interval; PRP, polyribosylribitol phosphate.
a Grade 3 pain at injection site = pain such that the infant cries when the limb is moved.
b Grade 3 = symptom that prevents normal everyday activities.
c Fever = axillary temperature.
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the study due to an AE.
Booster vaccination
Local symptoms were reported more commonly after the
booster dose, with pain redness or swelling reported by up to
70.7% of subjects (Table 4). In contrast, with the exception of
loss of appetite and fever, the incidence of general solicited
symptoms tended to be lower than that following primary
vaccination. Fever>39.0 8C and grade 3 loss of appetite were
uncommon. There was no appreciable difference between
groups (primed with DTPa—HBV/Hib or DTPa—HBV + Hib) in
terms of the incidence or intensity of solicited symptoms that
occurred after the booster dose of DTPa—HBV/Hib. Unsoli-
cited clinical events were reported by 102 subjects in theDTPa—HBV/Hib-primed group and 119 subjects in the DTPa—
HBV + Hib-primed group. One event (otitis media) was of
grade 3 intensity, but was not considered by the investigator
to be related to the booster dose. A total of nine SAEs were
reported, none of which were considered related to the study
vaccine. All subjects recovered, and none withdrew from the
study due to a SAE.
Discussion
A large range of combination vaccines, including DTPa—HBV,
DTPa—IPV, and DTPa—HBV—IPV (GlaxoSmithKline Biologicals)
have been developed, any of which can be reconstituted with
lyophilized conjugate Hib vaccine to provide protection
e48 H. Marshall et al.against up to six diseases in a single injection.10 The efficacy
and safety of such DTPa-based combinations have been
established in a range of clinical studies in infants, toddlers,
and school-age children.11,19—22
The study reported here evaluated the immunogenicity
and safety of DTPa—HBV and Hib vaccines administered as a
single mixed injection or as separate injections in opposite
limbs for primary vaccination in infants aged 2, 4, and 6
months. A follow-up study investigated the immunogenicity
and safety of booster vaccination with DTPa—HBV/Hib as a
single injection given in the second year of life. This study is
original in that plain PRP was used to demonstrate an ana-
mnestic response to a primary course of Hib vaccine in
children identified as non-responders and low responders
to Hib, prior to a booster Hib vaccination.
Primary immunization with the combined vaccine resulted
in high levels of seroprotection (94%) against the Hib PRP
antigen (defined as anti-PRP antibody 0.15 mg/ml) and 97%
seroprotection for separate injections. Similarly for hepatitis
B, no statistically significant differencewas observed between
the combined or separate methods of vaccine administration
with overlapping 95% CI for seroprotection rate. However the
proportion of subjects with anti-PRP antibody levels of
1.0 mg/ml, and anti-PRP antibody GMC, was higher in the
group that received separate injections. Concentrations of
specific anti-PRP antibody >0.15 mg/ml have traditionally
been associated with short-term protection against natural
infections, whereas concentrations >1.0 mg/ml have been
associated with long-term protection.23,24 It is well documen-
ted that the combined administration of Hib tetanus-conju-
gated vaccines with DTPa-based vaccines can reduce the level
of circulating antibodies to PRP compared to separate admin-
istration of the Hib vaccine.11,14,25 However, it has also been
shown that the functional nature of the antibodies against Hib
producedbycombinedDTPa-based/Hib vaccines is the sameas
those induced by separate injections, and that immunological
memory is induced.15,16
The results of the present study confirm these findings and
in addition demonstrate induction of immune memory to the
PRP antigen even in the lower responders. Indeed, a subset of
subjects with lower anti-PRP responses to primary vaccination
(definedusing an arbitrary cut-off to identify the 10%of lowest
responders in the primary vaccination study) who received an
injection of plain PRPat age 12—15months showedan increase
in mean anti-PRP GMC of over 7-fold. This response to PRP
challenge, at an age where no significant response to the
polysaccharide is expected, is indicative of immunological
memory and confirms the findings of other studies.22 The dose
of plain PRP in this study, mimicking Hib infection, was used to
demonstrate effective priming and immunological memory in
subjects who developed a lower antibody response to Hib. The
anamnestic response observed following plain PRP challenge
and the booster DTPa—HBV/Hib dose confirm results from
other studies with DTPa—Hib combination vaccines showing
induction of immune memory.17,25,26 In addition studies that
have examined the functional and qualitative characteristics
of antibodies have shown no difference between separate or
mixed Hib vaccine administration.15
The importance of a booster dose of Hib conjugate vaccine
in achieving effective and long-term immunity is well appre-
ciated.Missing the recommended booster dosewas associated
with an increase in Hib disease in Germany27 and with areduction in prevention of Hib colonization.28 Immunity after
primary vaccination without booster was shown to wane over
time in theUK,with a fall in vaccine effectiveness to 37.3% two
years post-vaccination.28,29 Concerns about the efficacy of Hib
in DTPa-based/Hib combination vaccines have been negated
by epidemiological data showing that when these vaccines
have been included in routine infant schedules they have been
highly successful in prevention of Hib disease.30
In terms of other vaccine antigens, the proportion of
subjects who developed seroprotective antibody concentra-
tions against diphtheria, tetanus, and hepatitis B or a vaccine
response to pertussis antigens after the booster dose was
high, and robust increases in antibody concentrations were
observed regardless of the vaccine administered for the
primary vaccination course.
Mixing of the DTPa—HBV and Hib vaccines did not result in
increased reactogenicity for either primary or booster vacci-
nation. In the booster study reported here, the combined
DTPa—HBV/Hib booster vaccinationwas found to be safe, with
no SAEs that were considered to be related to treatment, and
no withdrawals due to SAEs. There was however, a notable
increase in grade 3 pain and redness and swelling >20 mm
following the booster vaccinations in both groups. Booster
DTPa vaccination has been shown to be associated with a
higher rate of extensive local reactions than primary vaccina-
tion, the pathogenesis of which is likely to be multifactor-
ial.31,32 However, these local reactions have been shown to
resolve spontaneously without any resulting sequelae.33
In conclusion, DTPa—HBV and Hib vaccines have been
shown to be safe and immunogenic whether administered
as a single injection or as separate injections for primary
vaccination of infants at ages 2, 4, and 6 months. After
booster vaccination with combined DTPa—HBV/Hib vaccine
at age 18—19 months, 96—100% of subjects showed seropro-
tective/seropositive levels of antibodies against all vaccine
antigens, and induction of immune memory to PRP was
demonstrated in low—moderate responders.
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